Springer Nature
Browse
12957_2020_1792_MOESM3_ESM.tif (5.96 MB)

MOESM3 of Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis

Download (5.96 MB)
figure
posted on 2020-01-21, 05:11 authored by Jiahang Mo, Xiao Hu, Lihu Gu, Bangsheng Chen, Parikshit Khadaroo, Zefeng Shen, Lei Dong, Yuqi Lv, Marylin Chitumba, Jiequan Liu
Additional file 3: Figure S3. Forest plot of the long-term prognostic outcomes of anti-PD-1/PD-L1 monotherapy in NSCLC (Non-smoker vs. Smoker), PNon-smoker=0.921, PSmoker<0.001.

History